Trine Lindhardt Plesner

900 total citations
30 papers, 655 citations indexed

About

Trine Lindhardt Plesner is a scholar working on Pathology and Forensic Medicine, Genetics and Hematology. According to data from OpenAlex, Trine Lindhardt Plesner has authored 30 papers receiving a total of 655 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pathology and Forensic Medicine, 11 papers in Genetics and 11 papers in Hematology. Recurrent topics in Trine Lindhardt Plesner's work include Lymphoma Diagnosis and Treatment (13 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Multiple Myeloma Research and Treatments (7 papers). Trine Lindhardt Plesner is often cited by papers focused on Lymphoma Diagnosis and Treatment (13 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Multiple Myeloma Research and Treatments (7 papers). Trine Lindhardt Plesner collaborates with scholars based in Denmark, United States and United Kingdom. Trine Lindhardt Plesner's co-authors include Torben Plesner, Jean‐Marie Delaissé, Teis Esben Søndergaard, Frederik Dagnæs‐Hansen, Katarzyna Skórzyńska-Dziduszko, Thomas Levin Andersen, Ellen‐Margrethe Hauge, K Thorling, B. Egelund Christensen and JK Larsen and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and PLoS ONE.

In The Last Decade

Trine Lindhardt Plesner

27 papers receiving 638 citations

Peers

Countries citing papers authored by Trine Lindhardt Plesner

Since Specialization

Citations

This map shows the geographic impact of Trine Lindhardt Plesner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Trine Lindhardt Plesner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Trine Lindhardt Plesner more than expected).

Fields of papers citing papers by Trine Lindhardt Plesner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Trine Lindhardt Plesner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Trine Lindhardt Plesner. The network helps show where Trine Lindhardt Plesner may publish in the future.

Co-authorship network of co-authors of Trine Lindhardt Plesner

This figure shows the co-authorship network connecting the top 25 collaborators of Trine Lindhardt Plesner. A scholar is included among the top collaborators of Trine Lindhardt Plesner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Trine Lindhardt Plesner. Trine Lindhardt Plesner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Epidemiological evidence for the role of puberty and immune senescence in Hodgkin lymphoma aetiology from 1992 Danish cases 2025 ·International Journal of Cancer ·(unknown), Stephen Hamilton‐Dutoit, (unknown), (unknown), Trine Lindhardt Plesner, Peter Hollander, Peter C. Brown, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Ruth F. Jarrett, (unknown), (unknown), Lisa Lyngsie Hjalgrim, Ingrid Glimelius, (unknown)	0
2	Differential tumor protein expression at follicular lymphoma diagnosis reveals dysregulation of key molecular pathways associated with histological transformation 2024 ·Scientific Reports ·(unknown), Katharina Wolter, (unknown), Maja Dam Andersen, (unknown), (unknown), (unknown), Charlotte Madsen, Trine Lindhardt Plesner, Stephen Hamilton‐Dutoit, Bent Honoré, Maja Ludvigsen	1
3	Co-shared genomic alterations within tumors from patients with both myeloproliferative neoplasms and lymphoma 2024 ·Haematologica ·(unknown), Martin Bjerregård Pedersen, (unknown), Marcus Høy Hansen, (unknown), Trine Lindhardt Plesner, Henrik Frederiksen, (unknown), Stephen Hamilton‐Dutoit, (unknown), (unknown), Hans Beier Ommen, Jesper Stentoft, Wayne Tam, Maja Ludvigsen, Wing C. Chan, Nicolai J. Birkbak, Giorgio Inghirami, Francesco d’Amore	0
4	Impact of the Immune Landscape in Follicular Lymphoma: Insights into Histological Transformation in the Rituximab Era 2024 ·Cancers ·(unknown), Maria Fuglsang Jensen, Maja Dam Andersen, Trine Lindhardt Plesner, Stephen Hamilton‐Dutoit, Maja Ludvigsen	1
5	IDO1 Protein Is Expressed in Diagnostic Biopsies from Both Follicular and Transformed Follicular Patients 2023 ·International Journal of Molecular Sciences ·(unknown), (unknown), (unknown), Maja Dam Andersen, Charlotte Bernhard Madsen, (unknown), Bent Honoré, Francesco d’Amore, Trine Lindhardt Plesner, Stephen Hamilton‐Dutoit, Maja Ludvigsen	2
6	Proteomics identifies apoptotic markers as predictors of histological transformation in patients with follicular lymphoma 2023 ·Blood Advances ·(unknown), Katharina Wolter, Amanda Campbell, Maja Dam Andersen, (unknown), (unknown), Charlotte Bernhard Madsen, (unknown), Trine Lindhardt Plesner, Stephen Hamilton‐Dutoit, Bent Honoré, Maja Ludvigsen	8
7	PD-1 Expression in Pre-Treatment Follicular Lymphoma Predicts the Risk of Subsequent High-Grade Transformation 2021 ·OncoTargets and Therapy ·(unknown), Ida Monrad, Charlotte Bernhard Madsen, (unknown), Bent Honoré, Trine Lindhardt Plesner, Stephen Hamilton‐Dutoit, Francesco d’Amore, Maja Ludvigsen	13
8	STAT3 is over-activated within CD163pos bone marrow macrophages in both Multiple Myeloma and the benign pre-condition MGUS 2021 ·Cancer Immunology Immunotherapy ·Morten Nørgaard Andersen, Niels Frost Andersen, (unknown), Anders Etzerodt, Boe Sandahl Sørensen, Niels Abildgaard, Trine Lindhardt Plesner, Marianne Hokland, Holger Jon Møller	9
9	Glycolytic biomarkers predict transformation in patients with follicular lymphoma 2020 ·PLoS ONE ·Ida Monrad, Charlotte Madsen, (unknown), Bent Honoré, Trine Lindhardt Plesner, Stephen Hamilton‐Dutoit, Francesco d’Amore, Maja Ludvigsen	11
10	PF628 O-12-M1: AN EVALUATION OF TIME TO NEXT TREATMENT IN MELFLUFEN AND DEXAMETHASONE-TREATED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA 2019 ·HemaSphere ·Sara Bringhen, Paul G. Richardson, (unknown), Trine Lindhardt Plesner, (unknown), (unknown), Brandi Reeves, Stojan Zavisic, Johan Harmenberg, (unknown), Pieter Sonneveld	2
11	Lympho- and Myeloproliferative Malignancies Occurring in the Same Host: Description of a Nationwide Discovery Cohort 2017 ·(unknown), Trine Lindhardt Plesner, Martin Bjerregård Pedersen, Maja Ludvigsen, Henrik Frederiksen, Michael Møller, Rui Wang, Wayne Tam, Giorgio Inghirami, Francesco d’Amore	1
12	The CLEC12A receptor marks human basophils: Potential implications for minimal residual disease detection in acute myeloid leukemia 2017 ·Cytometry Part B Clinical Cytometry ·(unknown), Anne Stidsholt Roug, Trine Lindhardt Plesner, Lene Hyldahl Ebbesen, Gordon D. Brown, Line Nederby	9
13	Health-related quality of life in non-transplant eligible newly diagnosed multiple myeloma patients treated with melphalan/prednisolone plus either thalidomide or lenalidomide; results of the HOVON87/NMSG18 study 2017 ·Pure Amsterdam UMC ·(unknown), Claudia A.M. Stege, Birgit I. Lissenberg‐Witte, Bronno van der Holt, (unknown), Morten Salomo, (unknown), Markus Hansson, Trine Lindhardt Plesner, (unknown), Einar Haukås, Peter Gimsing, Pieter Sonneveld, Niels Abildgaard, Anders Waage, Sonja Zweegman	1
14	An open-label, randomised phase 3 study of daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): POLLUX 2016 ·Meletios Α. Dimopoulos, Albert Oriol, Hareth Nahi, Jesús F. San Miguel, (unknown), Neil Rabin, Robert Z. Orlowski, (unknown), Kazuyuki Suzuki, Trine Lindhardt Plesner	11
15	Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma 2016 ·Clinical Pharmacology & Therapeutics ·(unknown), Xiaoyu Yan, Thomas A. Puchalski, Sagar Lonial, HM Lokhorst, (unknown), Trine Lindhardt Plesner, Kui Liu, Imran Khan, (unknown), Tahamtan Ahmadi, Juan José Pérez Ruixo, Honghui Zhou, Pamela L. Clemens	48
16	PHARMACODYNAMIC RELATIONSHIP BETWEEN NATURAL KILLER CELLS AND DARATUMUMAB EXPOSURE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA 2016 ·Pure Amsterdam UMC ·Tineke Casneuf, Xiuping Xu, (unknown), Amy Axel, Bie Verbist, (unknown), Imran Khan, (unknown), (unknown), Sagar Lonial, Trine Lindhardt Plesner, H M Lokhorst, (unknown), Pamela L. Clemens, A. Kate Sasser	7
17	Safety and efficacy of first-line treatment with doxorubicin, cyclophosphamide, bortezomib, dexamethasone and lenalidomide (ACVDL) in newly diagnosed multiple myeloma patients of all ages 2015 ·Clinical Lymphoma Myeloma & Leukemia ·Kristian Andersen, Maja Hinge, (unknown), (unknown), Paw Christian Holdgaard, (unknown), Niels Pallisgaard, Gitte Kerndrup, Trine Lindhardt Plesner	2
18	In B-cell chronic lymphocytic leukaemia chromosome 17 abnormalities and not trisomy 12 are the single most important cytogenetic abnormalities for the prognosis: A cytogenetic and immunophenotypic study of 480 unselected newly diagnosed patients 1997 ·Leukemia Research ·Christian H. Geisler, Preben Philip, B. Egelund Christensen, K Hou-Jensen, Niels Tinggaård Pedersen, O. Myhre Jensen, K Thorling, Elo Andersen, Henrik Birgens, A Drivsholm, J Ellegaard, JK Larsen, Trine Lindhardt Plesner, Peter de Nully Brown, P. Andersen, Mogens Hansen	85
19	Quantitative buffy coat analysis in haematological patients compared to standard laboratory methods 1990 ·Scandinavian Journal of Clinical and Laboratory Investigation ·(unknown), (unknown), Trine Lindhardt Plesner	0
20	Familial myoglobinuria. A study of muscle and kidney pathophysiology in three brothers. 1983 ·PubMed ·(unknown), (unknown), (unknown), (unknown), (unknown), Trine Lindhardt Plesner, (unknown), Andersen, Svend Strandgaard	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact